The Efficacy of Sunitinib Treatment of Renal Cancer Cells Is Associated with the Protein PHAX In Vitro
Anti-angiogenic agents, such as the multi-tyrosine kinase inhibitor sunitinib, are key first line therapies for metastatic clear cell renal cell carcinoma (ccRCC), but their mechanism of action is not fully understood. Here, we take steps towards validating a computational prediction based on differ...
Main Authors: | Rafia S. Al-Lamki, Nicholas J. Hudson, John R. Bradley, Anne Y. Warren, Tim Eisen, Sarah J. Welsh, Antony C. P. Riddick, Fiach C. O’Mahony, Arran Turnbull, Thomas Powles, SCOTRRCC Collaborative, Antonio Reverter, David J. Harrison, Grant D. Stewart |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-04-01
|
Series: | Biology |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-7737/9/4/74 |
Similar Items
-
Caractérisation d'une nouvelle voie de biogenèse des petits ARN
by: Hallais, Marie
Published: (2010) -
Sunitinib: the antiangiogenic effects and beyond
by: Hao Z, et al.
Published: (2016-09-01) -
A significant response to sunitinib in a patient with anaplastic thyroid carcinoma
by: Enrique Grande, et al.
Published: (2013-01-01) -
Sunitinib resistance in renal cell carcinoma
by: Christudas Morais
Published: (2014-04-01) -
Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib
by: Keyvanjah Kiana, et al.
Published: (2012-08-01)